NEWLAND PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.6 CNY | +1.95% |
|
-7.23% | -8.51% |
| 04-24 | Newland Pharmaceutical Co., Ltd. Announces Board Elections | CI |
| 04-23 | Newland Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 3,850 | 4,163 |
| Enterprise Value (EV) 1 | 3,103 | 3,306 |
| P/E ratio | 22.4 x | 26.3 x |
| Yield | 1.73% | 1.92% |
| Capitalization / Revenue | 6.14 x | 6.39 x |
| EV / Revenue | 4.95 x | 5.07 x |
| EV / EBITDA | 18.5 x | 17.4 x |
| EV / FCF | -273,872,429 x | 20,795,712 x |
| FCF Yield | -0% | 0% |
| Price to Book | 2.84 x | 2.87 x |
| Nbr of stocks (in thousands) | 280,056 | 280,056 |
| Reference price 2 | 13.75 | 14.86 |
| Announcement Date | 30/03/23 | 25/03/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 295.1 | 406.5 | 433.1 | 513.8 | 627.4 | 651.4 |
| EBITDA 1 | 41.76 | 132.7 | 160.8 | 157.1 | 167.4 | 190.4 |
| EBIT 1 | 26.9 | 116.2 | 142.8 | 136.3 | 145.3 | 161.9 |
| Operating Margin | 9.12% | 28.59% | 32.97% | 26.53% | 23.16% | 24.85% |
| Earnings before Tax (EBT) 1 | 32.96 | 126.1 | 137.4 | 131.9 | 142.9 | 181.2 |
| Net income 1 | 28.59 | 109.2 | 118.5 | 115 | 132.3 | 159 |
| Net margin | 9.69% | 26.85% | 27.35% | 22.38% | 21.09% | 24.4% |
| EPS 2 | 0.1375 | 0.5238 | 0.5667 | 0.5475 | 0.6143 | 0.5643 |
| Free Cash Flow | - | 322.2 | -51.2 | -8.865 | -11.33 | 159 |
| FCF margin | - | 79.25% | -11.82% | -1.73% | -1.81% | 24.4% |
| FCF Conversion (EBITDA) | - | 242.87% | - | - | - | 83.49% |
| FCF Conversion (Net income) | - | 295.16% | - | - | - | 100% |
| Dividend per Share | - | - | - | - | 0.2381 | 0.2857 |
| Announcement Date | 27/06/21 | 27/06/21 | 27/06/21 | 27/10/22 | 30/03/23 | 25/03/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 95.1 | 16.1 | 73.7 | 83.4 | - | - |
| Net Cash position 1 | - | - | - | - | 747 | 857 |
| Leverage (Debt/EBITDA) | 2.278 x | 0.1215 x | 0.4584 x | 0.5312 x | - | - |
| Free Cash Flow | - | 322 | -51.2 | -8.86 | -11.3 | 159 |
| ROE (net income / shareholders' equity) | - | 37.5% | 46.9% | 31.9% | 14.9% | 11.2% |
| ROA (Net income/ Total Assets) | - | 14.2% | 18.6% | 14.3% | 8.25% | 6.44% |
| Assets 1 | - | 767.2 | 637.3 | 802.8 | 1,604 | 2,470 |
| Book Value Per Share 2 | 1.880 | 0.9200 | 1.490 | 1.920 | 4.840 | 5.170 |
| Cash Flow per Share 2 | 0.0400 | 0.1000 | 0.1700 | 0.1600 | 0.1800 | 0.9600 |
| Capex 1 | 8.42 | 9.71 | 17 | 25.4 | 74.3 | 96.5 |
| Capex / Sales | 2.85% | 2.39% | 3.92% | 4.94% | 11.85% | 14.82% |
| Announcement Date | 27/06/21 | 27/06/21 | 27/06/21 | 27/10/22 | 30/03/23 | 25/03/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -8.51% | 526M | |
| +45.82% | 765B | |
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| -0.78% | 219B | |
| +11.88% | 216B | |
| +5.90% | 164B |
- Stock Market
- Equities
- 301277 Stock
- Financials Newland Pharmaceutical Co., Ltd.